Axitinib in the treatment of metastatic renal cell carcinoma

Thai H. Ho, Eric Jonasch

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Axitinib, an oral small-molecule tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma. Common side effects include hypertension, fatigue and dysphonia. Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma. Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.

Original languageEnglish (US)
Pages (from-to)1247-1253
Number of pages7
JournalFuture Oncology
Issue number11
StatePublished - Nov 2011


  • AG 013736
  • AXIS
  • VEGF
  • angiogenesis
  • axitinib
  • renal cell carcinoma
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Axitinib in the treatment of metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this